X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Procter & Gamble Health - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs PROCTER & GAMBLE HEALTH - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

PROCTER & GAMBLE HEALTH 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA PROCTER & GAMBLE HEALTH ASTRAZENECA PHARMA/
PROCTER & GAMBLE HEALTH
 
P/E (TTM) x 86.9 60.7 143.1% View Chart
P/BV x 19.2 10.6 180.6% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 ASTRAZENECA PHARMA   PROCTER & GAMBLE HEALTH
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
PROCTER & GAMBLE HEALTH
Dec-17
ASTRAZENECA PHARMA/
PROCTER & GAMBLE HEALTH
5-Yr Chart
Click to enlarge
High Rs1,2781,358 94.1%   
Low Rs883933 94.6%   
Sales per share (Unadj.) Rs228.4665.0 34.3%  
Earnings per share (Unadj.) Rs10.456.6 18.3%  
Cash flow per share (Unadj.) Rs16.372.5 22.4%  
Dividends per share (Unadj.) Rs015.00 0.0%  
Dividend yield (eoy) %01.3 0.0%  
Book value per share (Unadj.) Rs98.8441.7 22.4%  
Shares outstanding (eoy) m25.0016.60 150.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.71.7 274.7%   
Avg P/E ratio x104.220.2 514.9%  
P/CF ratio (eoy) x66.415.8 420.5%  
Price / Book Value ratio x10.92.6 421.9%  
Dividend payout %026.5 0.0%   
Avg Mkt Cap Rs m27,00819,011 142.1%   
No. of employees `0001.41.5 87.8%   
Total wages/salary Rs m1,5351,696 90.5%   
Avg. sales/employee Rs Th4,210.97,150.0 58.9%   
Avg. wages/employee Rs Th1,132.21,098.7 103.1%   
Avg. net profit/employee Rs Th191.1608.2 31.4%   
INCOME DATA
Net Sales Rs m5,71011,040 51.7%  
Other income Rs m123240 51.1%   
Total revenues Rs m5,83311,279 51.7%   
Gross profit Rs m4631,376 33.6%  
Depreciation Rs m147264 55.8%   
Interest Rs m00-   
Profit before tax Rs m4381,352 32.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0170 0.0%   
Tax Rs m179583 30.7%   
Profit after tax Rs m259939 27.6%  
Gross profit margin %8.112.5 65.0%  
Effective tax rate %40.843.1 94.7%   
Net profit margin %4.58.5 53.3%  
BALANCE SHEET DATA
Current assets Rs m3,2097,523 42.7%   
Current liabilities Rs m2,0702,253 91.9%   
Net working cap to sales %20.047.7 41.8%  
Current ratio x1.63.3 46.4%  
Inventory Days Days7252 138.7%  
Debtors Days Days3541 86.1%  
Net fixed assets Rs m7901,240 63.7%   
Share capital Rs m50166 30.1%   
"Free" reserves Rs m2,4197,167 33.8%   
Net worth Rs m2,4697,333 33.7%   
Long term debt Rs m00-   
Total assets Rs m4,6059,912 46.5%  
Interest coverage xNMNM-  
Debt to equity ratio x00-  
Sales to assets ratio x1.21.1 111.3%   
Return on assets %5.69.5 59.4%  
Return on equity %10.512.8 81.9%  
Return on capital %17.720.8 85.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m3001,015 29.5%   
Fx outflow Rs m2,0153,043 66.2%   
Net fx Rs m-1,715-2,028 84.6%   
CASH FLOW
From Operations Rs m88537 16.4%  
From Investments Rs m-94-476 19.7%  
From Financial Activity Rs mNA-220 0.0%  
Net Cashflow Rs m-6-160 3.6%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 51.8 144.8%  
Indian inst/Mut Fund % 0.3 18.2 1.6%  
FIIs % 15.7 1.0 1,570.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 29.1 31.3%  
Shareholders   12,856 28,591 45.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   SANOFI INDIA  ABBOTT INDIA  FRESENIUS KABI ONCO.  WYETH LTD  TORRENT PHARMA  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Yes Bank's Road Ahead(Podcast)

The stock markets witnessed selling pressure in the week gone by. Market participants remained cautious tracking tepid quarterly earnings amid weak cues.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

MERCK Announces Quarterly Results (4QFY19); Net Profit Up 79.2% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

MERCK LTD Announces Quarterly Results (3QFY19); Net Profit Up 31.3% (Quarterly Result Update)

Mar 5, 2019 | Updated on Mar 5, 2019

For the quarter ended December 2018, MERCK LTD has posted a net profit of Rs 135 m (up 31.3% YoY). Sales on the other hand came in at Rs 2 bn (down 32.8% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Here's What to Do with Falling Small Cap Stocks(Profit Hunter)

Jul 10, 2019

There are some great buying opportunities in the market right now - and the small cap space is your best bet.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock(The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jul 19, 2019 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS